MX2021011635A - Compuesto para el secuestro de anticuerpos no deseables en un paciente. - Google Patents

Compuesto para el secuestro de anticuerpos no deseables en un paciente.

Info

Publication number
MX2021011635A
MX2021011635A MX2021011635A MX2021011635A MX2021011635A MX 2021011635 A MX2021011635 A MX 2021011635A MX 2021011635 A MX2021011635 A MX 2021011635A MX 2021011635 A MX2021011635 A MX 2021011635A MX 2021011635 A MX2021011635 A MX 2021011635A
Authority
MX
Mexico
Prior art keywords
peptide
compound
sub
sequestration
patient
Prior art date
Application number
MX2021011635A
Other languages
English (en)
Inventor
Bettina Wanko
Oskar Smrzka
Original Assignee
Ablevia Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablevia Biotech Gmbh filed Critical Ablevia Biotech Gmbh
Publication of MX2021011635A publication Critical patent/MX2021011635A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un compuesto para el secuestro de anticuerpos no deseables (por ejemplo, relacionados con una enfermedad autoinmune) en un paciente. El compuesto comprende un andamio de biopolímero inerte y al menos un primer péptido n-mer de la fórmula general P ( - S - P )(n-1) y un segundo péptido n-mer de la fórmula general P ( - S - P )(n-1); en donde, independientemente de cada aparición, P es un péptido con una longitud de secuencia de 2-13 aminoácidos y S es un espaciador no peptídico, en donde, independientemente para cada uno de los péptidos n-mers, n es un número entero de al menos 1, en donde cada uno de los péptidos n-mers está unido al andamio de biopolímero. También se proporcionan composiciones farmacéuticas que comprenden el compuesto, así como un método para secuestrar uno o más anticuerpos presentes en un individuo y un método para inhibir una reacción inmune para un tratamiento con un agente activo.
MX2021011635A 2019-03-23 2020-03-23 Compuesto para el secuestro de anticuerpos no deseables en un paciente. MX2021011635A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19164784.1A EP3715374A1 (en) 2019-03-23 2019-03-23 Compound for the sequestration of undesirable antibodies in a patient
PCT/EP2020/058024 WO2020193486A1 (en) 2019-03-23 2020-03-23 Compound for the sequestration of undesirable antibodies in a patient

Publications (1)

Publication Number Publication Date
MX2021011635A true MX2021011635A (es) 2022-01-04

Family

ID=65991526

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011635A MX2021011635A (es) 2019-03-23 2020-03-23 Compuesto para el secuestro de anticuerpos no deseables en un paciente.

Country Status (17)

Country Link
US (1) US20220062435A1 (es)
EP (3) EP3715374A1 (es)
JP (1) JP2022528736A (es)
KR (1) KR20210142615A (es)
CN (1) CN113631581A (es)
AR (1) AR121036A1 (es)
AU (1) AU2020249341A1 (es)
BR (1) BR112021018171A2 (es)
CA (1) CA3130187A1 (es)
DK (1) DK3898702T3 (es)
EA (1) EA202192085A1 (es)
ES (1) ES2927642T3 (es)
IL (1) IL286589A (es)
MX (1) MX2021011635A (es)
SG (1) SG11202108756TA (es)
TW (1) TW202102520A (es)
WO (1) WO2020193486A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11986536B2 (en) * 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
TW202228784A (zh) * 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
MX2023003377A (es) * 2020-09-23 2023-03-31 Ablevia Biotech Gmbh Compuesto para aumentar la eficacia de los vectores virales.
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5372933A (en) 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US6897287B1 (en) 1990-01-31 2005-05-24 Oklahoma Medical Research Foundation Ro/SSA peptide reagents for diagnosis of autoantibodies
US7888458B1 (en) 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
EP1135167A2 (en) 1998-12-09 2001-09-26 La Jolla Pharmaceutical Methods and formulations for reducing circulating antibodies
WO2004067549A2 (de) 2003-01-31 2004-08-12 Max-Delbrück-Centrum für Molekulare Medizin Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung
US20040258683A1 (en) 2003-03-30 2004-12-23 Linnik Matthew D. Methods of treating and monitoring systemic lupus erythematosus in individuals
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US8210547B2 (en) 2009-06-16 2012-07-03 Toyota Motor Engineering & Manufacturing North America, Inc. Active magneto-rheological spring assemblies and vehicle suspension systems incorporating the same
US20130079280A1 (en) 2010-04-13 2013-03-28 Medlmmune, Llc Fibronectin type iii domain-based multimeric scaffolds
EP2402016A1 (en) 2010-06-29 2012-01-04 Charité - Universitätsmedizin Berlin Aptamers that inhibit interaction between antibody and 1st or 2nd extracellular loop of human beta-1-adrenergic receptor
JP4857396B1 (ja) 2011-04-13 2012-01-18 日本製薬株式会社 融合蛋白質
WO2015056713A1 (ja) 2013-10-15 2015-04-23 国立大学法人東京大学 ｃ－Ｍｅｔタンパク質アゴニスト
PL3116887T3 (pl) 2014-03-13 2021-09-06 Universität Basel Ligandy węglowodanowe, które wiążą się z przeciwciałami igm przeciwko glikoproteinie związanej z mieliną
WO2015181393A1 (en) * 2014-05-30 2015-12-03 Per-Johan Jakobsson Novel sfti and cyclotide based peptides
EP2982756A1 (en) 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamers for use against autoantibody-associated diseases
JP6849667B2 (ja) 2015-09-16 2021-03-24 ウニヴェルズィテート バーゼル スフィンゴ糖脂質の糖鎖エピトープに対する抗体に結合する炭水化物リガンド
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
ES2858091T3 (es) 2016-06-20 2021-09-29 F Star Therapeutics Ltd Moléculas de unión que se unen a PD-L1 y LAG-3
CN110799210A (zh) 2016-12-02 2020-02-14 得克萨斯A&M大学系统 选择性消耗抗原特异性抗体的融合蛋白

Also Published As

Publication number Publication date
EP3898702B1 (en) 2022-06-29
KR20210142615A (ko) 2021-11-25
DK3898702T3 (da) 2022-09-26
EP3960769A1 (en) 2022-03-02
CN113631581A (zh) 2021-11-09
CA3130187A1 (en) 2020-10-01
EP3898702A1 (en) 2021-10-27
WO2020193486A1 (en) 2020-10-01
BR112021018171A2 (pt) 2021-11-16
US20220062435A1 (en) 2022-03-03
JP2022528736A (ja) 2022-06-15
AU2020249341A1 (en) 2021-11-18
TW202102520A (zh) 2021-01-16
AR121036A1 (es) 2022-04-13
IL286589A (en) 2021-12-01
ES2927642T3 (es) 2022-11-08
SG11202108756TA (en) 2021-10-28
EP3715374A1 (en) 2020-09-30
EA202192085A1 (ru) 2021-12-10

Similar Documents

Publication Publication Date Title
MX2021011635A (es) Compuesto para el secuestro de anticuerpos no deseables en un paciente.
CY1121877T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
ATE254630T1 (de) Cyclosporine
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
HUP0202367A2 (hu) FAP-aktivált tumorellenes peptidek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
AU2003299519A1 (en) Hepatitis c virus inhibitors
AU2003248535A1 (en) Heterocyclicsulfonamide hepatitis c virus inhibitors
MY140710A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
EP2423207A3 (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
WO2010068761A3 (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
ATE154013T1 (de) Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
BR112013003101A2 (pt) inibidores do vírus da hepatite c
GB2431404A (en) Peptide
ATE383850T1 (de) Pulver enthaltend neuartige oligosaccharidgemische und verfahren zu deren herstellung
WO2009042668A3 (en) Urea-containing peptides as inhibitors of viral replication
NO20072478L (no) Salter av isofosforamidsennep og analoger av disse som antitumor midler
MX2023003377A (es) Compuesto para aumentar la eficacia de los vectores virales.
JP2019534317A5 (es)
RU2015147247A (ru) Новые соединения, обладающие тройной активностью, тромболизисной, антитромботической и захвата радикалов, и их синтез, наноструктуры и применение
EA202192925A1 (ru) Твердые формы ингибитора glyt1
HUP0401080A2 (hu) Új görcsoldó sószármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
WO2009095162A8 (en) Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
RU2009117220A (ru) Антибактериальные и противовирусные пептиды из actinomadura namibiensis
MX2012001200A (es) (aza)indolizinacarboxamidas ciclicas, su preparacion y su uso como agentes farmaceuticos.
BRPI0513741A (pt) processo de melhoria da imunogeneicidade de um imunogene, antìgeno ou hapteno, complexo imunogênico, ácido nucleico e utilização de um complexo imunogênico